Roche Divarasib Phase 3 Trial: 44% Lower Risk of Death in Lung Cancer
The Roche divarasib Phase 3 trial cut the risk of death by 44% in previously treated KRAS G12C lung cancer. Survival, response and safety data.
The Roche divarasib Phase 3 trial cut the risk of death by 44% in previously treated KRAS G12C lung cancer. Survival, response and safety data.